Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10935262 | 0.85 | — | — | |
| SCHEMBL5485766 | 0.83 | — | — | |
| SCHEMBL28992261 | 0.80 | — | — | |
| SCHEMBL733409 | 0.79 | ALDH1A1 (0.43) | ALDH1A1TDP1LOXLOXL3LOXL2 | |
| SCHEMBL29285237 | 0.77 | — | — | |
| SCHEMBL22652 | 0.75 | — | — | |
| SCHEMBL8923972 | 0.75 | ALDH1A1 (0.33) | ALDH1A1TDP1 | |
| Water SCHEMBL6908198 | 0.75 | LPAR3 (0.41) | ALDH1A1TDP1 | |
| SCHEMBL413500 | 0.75 | — | — | |
| SCHEMBL4886947 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111578-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| WO-2025111578-A1 | LINKERS COUPLING FUNCTIONAL LIGANDS TO MACROMOLECULES | OLIX US, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| CN-112426538-A | micro-RNAs and compositions comprising micro-RNAs | 耶达研究及发展有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-112055749-A | Use of FUBP1 inhibitors for the treatment of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2020-12-08 | — | — | CN | disclosed |
| CN-107115352-B | micro-RNAs and compositions comprising micro-RNAs | 耶达研究及发展有限公司 | 2020-10-30 | — | — | CN | disclosed |
| CN-110291104-A | Compounds having anti-tumor activity against cancer cells carrying an EGFR or HER2 exon 20 mutation | 得克萨斯州大学系统董事会 | 2019-09-27 | — | — | CN | disclosed |
| CN-107988227-A | Efficient nanoparticle form double helix widow RNA structures and preparation method thereof | 株式会社百奥尼 | 2018-05-04 | — | — | CN | disclosed |
| CN-105705639-A | Dengue virus-specific sirna, double helix oligo-rna structure comprising sirna, and composition for suppressing proliferation of dengue virus comprising rna structure | 柏业公司 | 2016-06-22 | — | — | CN | disclosed |
| CN-104114704-A | High-efficiency nanoparticle-type double-helix oligo-RNA structure and preparation method thereof | BIONEER CORP | 2014-10-22 | — | — | CN | disclosed |
| US-20110166043-A1 | BIOMARKER DETECTION-2 | ATERIS TECHNOLOGIES, LLC | 2011-07-07 | — | — | US | disclosed |
| CN-1075336-A | Novel biological process for the preparation of 7-ADCA | MERCK & CO INC (US) | 1993-08-18 | — | — | CN | disclosed |
| CN-1074484-A | The new biological method of preparation 7-ACA and 7-ADAC | MERCK & CO INC (US) | 1993-07-21 | — | — | CN | disclosed |
| EP-0538404-A4 | FIBROBLAST GROWTH FACTOR RECEPTORS | — | 1993-05-26 | — | — | EP | disclosed |
| EP-0538404-A1 | FIBROBLAST GROWTH FACTOR RECEPTORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1993-04-28 | — | — | EP | disclosed |
| CN-1062169-A | PICHIA PASTORIS ACID PHOSPHATAE GENE | PHILLIPS PETROLEUM CO (US) | 1992-06-24 | — | — | CN | disclosed |
| WO-1992000999-A1 | FIBROBLAST GROWTH FACTOR RECEPTORS | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1992-01-23 | — | — | WO | disclosed |
| CN-1050044-A | As vaccine or be used for the treatment of the defective hepatitis virus of liver disease | UNIV YALE (US) | 1991-03-20 | — | — | CN | disclosed |
| CN-1040053-A | S before the expression hepatitis B in methylotrophic yeast 2Albumen | PHILLIPS PETROLEUM CO (US) | 1990-02-28 | — | — | CN | disclosed |
| CN-1039616-A | PICHIA PASTORIS ALCOHOL OXIDASE II REGULATORY REGION | PHILLIPS PETROLEUM CO (US) | 1990-02-14 | — | — | CN | disclosed |
| CN-1038668-A | In methylotrophic yeasts, express hepatitis B S and pre-s2 protein | PHILLIPS PETROLEUM CO (US) | 1990-01-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166043-A1 | BIOMARKER DETECTION-2 | CPB2, NAALAD2, PRSS2 | ALDH1A1 1052/4885TDP1 2173/4885LOX 2047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.